Simply Wall St.
Humana Faces Pay Oversight Push While Expanding Cardiac Care Programs
📊
AI Sentiment
Positive
6/10
- Home
- HUM
HUM
Humana Inc.
as of 03-09-2026 3:53pm EST
$178.26
$1.26
-0.70%
Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
| Founded: | 1961 | Country: | United States |
| Employees: | N/A | City: | LOUISVILLE |
| Market Cap: | 22.5B | IPO Year: | 2002 |
| Target Price: | $241.60 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Hold | Number of Analysts: | 20 |
| Dividend Yield: | Dividend Payout Frequency: | annual | |
| EPS: | 9.84 | EPS Growth: | -1.40 |
| 52 Week Low/High: | $169.61 - $315.35 | Next Earning Date: | 05-13-2026 |
| Revenue: | $129,664,000,000 | Revenue Growth: | 10.11% |
| Revenue Growth (this year): | 24.46% | Revenue Growth (next year): | 6.58% |
| P/E Ratio: | 18.24 | Index: | |
| Free Cash Flow: | 375.0M | FCF Growth: | -84.32% |
Stock Insider Trading Activity of Humana Inc. (HUM)
Shetty Sanjay K
Buy
President, CenterWell
HUM Feb 23, 2026
Avg Cost/Share
$185.21
Shares
810
Total Value
$150,016.05
Owned After
11,657
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Shetty Sanjay K | HUM | President, CenterWell | Feb 23, 2026 | Buy | $185.21 | 810 | $150,016.05 | 11,657 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 11, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYFeb 11, 2026 · 100% conf.
AI Prediction BUY
1D
+1.09%
$176.91
5D
+4.54%
$182.94
20D
+3.69%
$181.46
Price: $175.00 Prob +5D: 100% AUC: 1.000
0000049071-26-000005
hum-202602110000049071false00000490712026-02-112026-02-110000049071dei:FormerAddressMember2026-02-112026-02-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2026 (February 11, 2026)
Humana Inc.
(Exact name of registrant as specified in its charter)
Delaware1-597561-0647538 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
101 East Main Street, Louisville, KY 40202 (Address of principal executive offices, including zip code)
502-580-1000 (Registrant’s telephone number, including area code)
500 West Main Street, Louisville, KY 40202 (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common StockHUMNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
Item 7.01 Regulation FD Disclosure. Humana Inc. (the "Company") issued a press release this morning reporting financial results for the quarter ended December 31, 2025, and posted a detailed earnings release related to the same period to the Investor Relations portion of the Company’s website at www.humana.com. A copy of each release is attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and each release is incorporated herein by reference. Additionally, a copy of management's prepared remarks on the Company's 2025 financial results and expectations for future earnings, is attached hereto as Exhibit 99.3, and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits:
Exhibit No.Description
99.1Press Release
99.2Earnings Release and Statistical Pages
99.3Prepared Management Remarks
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
HUMANA INC.
BY:/s/ John-Paul W. Felter John-Paul W. Felter Senior Vice President, Chief Accounting Officer & Controller (Principal Accounting Officer)
Dated: February 11, 2026
2025 Q3 Q3 2025 Earnings
8-K Nov 5, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 5, 2025
0000049071-25-000055
hum-202511050000049071false00000490712025-11-052025-11-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2025 (November 5, 2025)
Humana Inc.
(Exact name of registrant as specified in its charter)
Delaware1-597561-0647538 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
500 West Main Street Louisville, KY 40202 (Address of principal executive offices, including zip code)
502-580-1000 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common StockHUMNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
Item 7.01 Regulation FD Disclosure. Humana Inc. (the "Company") issued a press release this morning reporting financial results for the quarter ended September 30, 2025, and posted a detailed earnings release related to the same period to the Investor Relations portion of the Company’s website at www.humana.com. A copy of each release is attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and each release is incorporated herein by reference. Additionally, a copy of management's prepared remarks on the Company's financial results for the quarter ended September 30, 2025 and expectations for future earnings, is attached hereto as Exhibit 99.3, and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits:
Exhibit No.Description
99.1Press Release
99.2Earnings Release and Statistical Pages
99.3Prepared Management Remarks
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
HUMANA INC.
BY:/s/ John-Paul W. Felter John-Paul W. Felter Senior Vice President, Chief Accounting Officer & Controller (Principal Accounting Officer)
Dated: November 5, 2025
2025 Q2 Q2 2025 Earnings
8-K Jul 30, 2025
2025
Q2
Q2 2025 Earnings
8-KJul 30, 2025
0000049071-25-000039
hum-202507300000049071false00000490712025-07-302025-07-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 (July 30, 2025)
Humana Inc.
(Exact name of registrant as specified in its charter)
Delaware1-597561-0647538 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
500 West Main Street Louisville, KY 40202 (Address of principal executive offices, including zip code)
502-580-1000 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common StockHUMNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
Item 7.01 Regulation FD Disclosure. Humana Inc. (the "Company") issued a press release this morning reporting financial results for the quarter ended June 30, 2025, and posted a detailed earnings release related to the same period to the Investor Relations portion of the Company’s website at www.humana.com. A copy of each release is attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and each release is incorporated herein by reference. Additionally, a copy of management's prepared remarks on the Company's financial results for the quarter ended June 30, 2025 and expectations for future earnings, is attached hereto as Exhibit 99.3, and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits:
Exhibit No.Description
99.1Press Release
99.2Earnings Release and Statistical Pages
99.3Prepared Management Remarks
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
HUMANA INC.
BY:/s/ John-Paul W. Felter John-Paul W. Felter Senior Vice President, Chief Accounting Officer & Controller (Principal Accounting Officer)
Dated: July 30, 2025
Latest Humana Inc. News
HUM Breaking Stock News: Dive into HUM Ticker-Specific Updates for Smart Investing
Business Wire
AM Best Assigns Issue Credit Rating to Humana Inc.’s New Junior Subordinated Notes
➖
AI Sentiment
Neutral
4/10
Business Wire
Humana Prices $1.0 Billion Fixed-to-Fixed Rate Junior Subordinated Notes Offering
📉
AI Sentiment
Negative
3/10
Reuters
CVS taps Google Cloud to roll out AI-powered health platform
📈
AI Sentiment
Highly Positive
8/10
GlobeNewswire
Humana partners with Disabled American Veterans for the sixth year
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
Is It Time To Reassess Humana (HUM) After Its Steep Share Price Slide
➖
AI Sentiment
Neutral
5/10
MarketBeat
AdaptHealth Conference: CFO Details CPAP Recurring Revenue, Faster Setups, and Capitated Contract Growth
📈
AI Sentiment
Highly Positive
9/10
Compare HUM vs Leading Stocks
See how HUM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "HUM Humana Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.